CHICAGO (AP) — CHICAGO (AP) — Xeris Biopharma Holdings, Inc. (XERS) on Thursday reported a loss of $5.1 million in its fourth quarter. The Chicago-based company said it had a loss of 3 cents ...

H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Xeris Biopharma (XERS) to $8 from $6.60 and keeps a Buy rating on the shares. The company’s first-time 2025 guidance for $ ...

Xeris Biopharma Holdings Inc (NASDAQ:XERS) exceeded its full-year guidance with total revenue of over $203 million, marking a 24% growth compared to the previous year. The company reported a 28% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Xeris Pharmaceuticals Inc. (XERS), with a market capitalization of $562 million, reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of -0.03, compared ...

Shares of Xeris Biopharma climbed after the company guided for higher revenue in 2025. The stock was up 17%, to $4.41, in Thursday trading, which is equivalent to the highest close since June 28 ...

Xeris Biopharma (XERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.10 per share a year ago. These figures ...